Zobrazeno 1 - 6 of 6 pro vyhledávání: '"Yuefeng Zou"'
2
Akademický článek
Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer
Autor: Bin Li, Jinping Zhang, Tao Wang, Yuhua Huang, Yifeng Xu, Chao Wang, Tianhang Zhai, Weifeng Huang, Zhijun Yuan, Shuang Dai, Shaogang Peng, Tuling Pang, Wenchao Jiang, Yuefeng Zou, Yingda Xu, Joanne Sun, Xinjiang Gong, Andy Tsun, Xiaoniu Miao
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Background The discovery of checkpoint inhibitors towards cytotoxic T-lymphocyte protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) has been revolutionary for the treatment of cancers. These therapies have only offered an average of 20%–
Externí odkaz: https://doaj.org/article/3e340593657c4bfda3b3c3eb21844f31
Zobrazit plný text záznamu
3
Akademický článek
A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy
Autor: Xiaoniu Miao, Yi Luo, Xi Huang, Suki M. Y. Lee, Zhijun Yuan, Yongzhou Tang, Liandi Chen, Chao Wang, Fan Wu, Yifeng Xu, Wenchao Jiang, Wei Gao, Xuedong Song, Yao Yan, Tuling Pang, Cheng Chen, Yuefeng Zou, Weihui Fu, Liping Wan, Javier Gilbert-Jaramillo, Michael Knight, Tiong Kit Tan, Pramila Rijal, Alain Townsend, Joanne Sun, Xiaolin Liu, William James, Andy Tsun, Yingda Xu
Publikováno v: mAbs, Vol 12, Iss 1 (2020)
In the absence of a proven effective vaccine preventing infection by SARS-CoV-2, or a proven drug to treat COVID-19, the positive results of passive immune therapy using convalescent serum provide a strong lead. We have developed a new class of tetra
Externí odkaz: https://doaj.org/article/53afdecd758e417bb4dadf7b82ae0045
Zobrazit plný text záznamu
4
895 Discovery of a safer 4–1BB agonist by targeting a membrane-proximal epitope combined with bispecific-mediated cross-bridging
Autor: Tao Wang, Tuling Pang, Xinjiang Gong, Yuhua Huang, Yuefeng Zou, Tianhang Zhai, Yingda Xu, Xiaoniu Miao, Joanne Sun, Shaogang Peng, Weifeng Huang, Bin Li, Yifeng Xu, Zhijun Yuan, Andy Tsun, Chao Wang, Shuang Dai, Wenchao Jiang
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundCheckpoint inhibitors towards cytotoxic T-lymphocyte protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) have paved the way for a new frontier of anti-cancer therapies that modulate our pre-existing immune system to fight against
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da027877d51e3effb70fddf539107d99
https://doaj.org/article/3dbbec51dffb4bd1af30fea60b05704e
Zobrazit plný text záznamu
5
Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer
Autor: Tuling Pang, Jin-Ping Zhang, Joanne Sun, Tianhang Zhai, Andy Tsun, Yifeng Xu, Wenchao Jiang, Tao Wang, Xiaoniu Miao, Zhijun Yuan, Shuang Dai, Chao Wang, Weifeng Huang, Shaogang Peng, Yuhua Huang, Bin Li, Yingda Xu, Yuefeng Zou, Xinjiang Gong
Publikováno v: Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
BackgroundThe discovery of checkpoint inhibitors towards cytotoxic T-lymphocyte protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) has been revolutionary for the treatment of cancers. These therapies have only offered an average of 20%–3
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cae1e61f7d297b7a3feb7a6648e9a98a
http://europepmc.org/articles/PMC8237747
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje